Status:
COMPLETED
12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
40+ years
Phase:
PHASE3
Brief Summary
The primary objective was to compare the bronchodilator efficacy of two doses (5 mcg and 10 mcg) of tiotropium inhalation solution delivered by the Respimat inhaler once daily to placebo and to ipratr...
Eligibility Criteria
Inclusion
- Outpatients of either sex, aged \>/= 40 years with a diagnosis of COPD (FEV1 \</= 60% predicted \[ECCS criteria\] and FEV1/FVC \</= 70%)
Exclusion
Key Trial Info
Start Date :
November 1 2002
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
491 Patients enrolled
Trial Details
Trial ID
NCT00240435
Start Date
November 1 2002
Last Update
November 1 2013
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
2
Boehringer Ingelheim Investigational Site
Downey, California, United States
3
University of California - Los Angeles
Los Angeles, California, United States
4
Boehringer Ingelheim Investigational Site
Palo Alto, California, United States